Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway

Fig. 1

Exposure was modeled considering (A) Fixed exposure (use or non-use) both pre-diagnosis (≤ 6 months prior to diagnosis) and baseline post-diagnosis (> 30 days and ≤ 305 days (10 months) following diagnosis); and (B) updated post-diagnosis exposure over follow-up considering never, current, and past use and updated cumulative defined daily dose (DDD) with a nine-month lagged exposure update introduced to reduce the effect of reverse causation

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us